These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 21941853)

  • 1. [Current and future views from pharmaceutical industry perspectives on development of antidepressants].
    Arano I; Imaeda T
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2011 Aug; 31(4):181-6. PubMed ID: 21941853
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Study designs and outcomes in antidepressant clinical trials.
    Khan A; Schwartz K
    Essent Psychopharmacol; 2005; 6(4):221-6. PubMed ID: 16041918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Development of a Guideline on Clinical investigation of Medicinal Product in the Treatment of Depression in Japan].
    Nakabayashi T
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2011 Aug; 31(4):169-76. PubMed ID: 21941851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Expectation for future development of antidepressant based on the newly published guideline focusing on clinical evaluation of antidepressants].
    Uyama Y
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2011 Aug; 31(4):177-80. PubMed ID: 21941852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Placebo-controlled antidepressant drug trials. Considering the ethical implications].
    Deisenhammer EA; Hinterhuber H
    Fortschr Neurol Psychiatr; 2003 May; 71(5):243-8. PubMed ID: 12740755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effective global drug development strategy for obtaining regulatory approval in Japan in the context of ethnicity-related drug response factors.
    Ichimaru K; Toyoshima S; Uyama Y
    Clin Pharmacol Ther; 2010 Mar; 87(3):362-6. PubMed ID: 20107436
    [No Abstract]   [Full Text] [Related]  

  • 7. [Drug development in Japan from the viewpoints of global pharmaceutical companies].
    Seriu T
    Rinsho Ketsueki; 2009 Jul; 50(7):556-62. PubMed ID: 19638723
    [No Abstract]   [Full Text] [Related]  

  • 8. Current status and future prospects of toxicogenomics in drug discovery.
    Khan SR; Baghdasarian A; Fahlman RP; Michail K; Siraki AG
    Drug Discov Today; 2014 May; 19(5):562-78. PubMed ID: 24216320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy in long-term treatment of depression.
    Montgomery SA
    J Clin Psychiatry; 1996; 57 Suppl 2():24-30. PubMed ID: 8626360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The changing horizon in the treatment of depression: scientific/clinical publication overview.
    Stokes PE
    J Clin Psychiatry; 1991 May; 52 Suppl():35-43. PubMed ID: 2030102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Our policy and future tasks related to ICH in anti-cancer drug development--a discussion from the viewpoint of an enterprise].
    Ekimoto H
    Gan To Kagaku Ryoho; 1997 Jan; 24(2):229-37. PubMed ID: 9030236
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Post launch studies].
    Akaza H; Ohashi Y; Shimada Y; Ikeda T; Saijo N; Isonishi S; Hirao Y; Tsuruo T; Tsukagoshi S; Sone S; Nakamura S; Kato M; Mikami O; von Euler M; Blackledge G; Milsted B; Vose B
    Gan To Kagaku Ryoho; 2002 Nov; 29(11):2037-48. PubMed ID: 12465411
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Participation in the international multi-countries study-operational issues from company view point].
    Hada S
    Gan To Kagaku Ryoho; 2007 Feb; 34(2):324-7. PubMed ID: 17301555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Infrastructure for new drug development to treat muscular dystrophy: current status of patient registration (remudy)].
    Nakamura H; Kimura E; Kawai M
    Brain Nerve; 2011 Nov; 63(11):1279-84. PubMed ID: 22068481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is it ethical to conduct placebo-controlled clinical trials in the development of new agents for osteoporosis? An industry perspective.
    Rosenblatt M
    J Bone Miner Res; 2003 Jun; 18(6):1142-5. PubMed ID: 12817772
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Operational aspect of participation in the multi-national clinical trials from the foreign pharmaceutical company's standpoint].
    Namazu K
    Gan To Kagaku Ryoho; 2007 Feb; 34(2):328-30. PubMed ID: 17301556
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brazil: An emerging partner in drug R&D.
    Rodrigues DG
    IDrugs; 2009 Aug; 12(8):497-502. PubMed ID: 19629884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current status and problems in development of molecular target agents for gastrointestinal malignancy in Japan.
    Boku N
    Jpn J Clin Oncol; 2010 Mar; 40(3):183-7. PubMed ID: 20047861
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analyzing global trends of biomarker use in drug interventional clinical studies.
    Hayashi K; Masuda S; Kimura H
    Drug Discov Ther; 2012 Apr; 6(2):102-7. PubMed ID: 22622020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
    Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
    Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.